Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Salam Awenat, Arnoldo Piccardo, Patricia Carvoeiras, Giovanni Signore, Luca Giovanella, John O Prior, Giorgio Treglia, Salam Awenat, Arnoldo Piccardo, Patricia Carvoeiras, Giovanni Signore, Luca Giovanella, John O Prior, Giorgio Treglia

Abstract

Background: The use of prostate-specific membrane antigen (PSMA)-targeted agents for staging prostate cancer (PCa) patients using positron emission tomography/computed tomography (PET/CT) is increasing worldwide. We performed a systematic review on the role of 18F-PSMA-1007 PET/CT in PCa staging to provide evidence-based data in this setting.

Methods: A comprehensive computer literature search of PubMed/MEDLINE and Cochrane Library databases for studies using 18F-PSMA-1007 PET/CT in PCa staging was performed until 31 December 2020. Eligible articles were selected and relevant information was extracted from the original articles by two authors independently.

Results: Eight articles (369 patients) evaluating the role of 18F-PSMA-1007 PET/CT in PCa staging were selected. These studies were quite heterogeneous, but, overall, they demonstrated a good diagnostic accuracy of 18F-PSMA-1007 PET/CT in detecting PCa lesions at staging. Overall, higher primary PCa aggressiveness was associated with higher 18F-PSMA-1007 uptake. When compared with other radiological and scintigraphic imaging methods, 18F-PSMA-1007 PET/CT had superior sensitivity in detecting metastatic disease and the highest inter-reader agreement. 18F-PSMA-1007 PET/CT showed similar results in terms of diagnostic accuracy for PCa staging compared with PET/CT with other PSMA-targeted tracers. Dual imaging with multi-parametric magnetic resonance imaging and 18F-PSMA-1007 PET/CT may improve staging of primary PCa. Notably, 18F-PSMA-1007-PET/CT may detect metastatic disease in a significant number of patients with negative standard imaging.

Conclusions: 18F-PSMA-1007 PET/CT demonstrated a good accuracy in PCa staging, with similar results compared with other PSMA-targeted radiopharmaceuticals. This method could substitute bone scintigraphy and conventional abdominal imaging for PCa staging. Prospective multicentric studies are needed to confirm these findings.

Keywords: PET; PSMA; PSMA-1007; prostate cancer; staging; systematic review.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the search for eligible studies on the diagnostic role of 18F-PSMA-1007 positron emission tomography/computed tomography (PET/CT) in prostate cancer staging. PSMA, prostate-specific membrane antigen.

References

    1. Hassanipour-Azgomi S., Mohammadian-Hafshejani A., Ghoncheh M., Towhidi F., Jamehshorani S., Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016;4:118–124. doi: 10.1016/j.prnil.2016.07.001.
    1. Schiavina R., Chessa F., Borghesi M., Gaudiano C., Bianchi L., Corcioni B., Castellucci P., Ceci F., Ceravolo I., Barchetti G., et al. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. Int. J. Urol. 2018;26:18–30. doi: 10.1111/iju.13797.
    1. Fanti S., Minozzi S., Antoch G., Banks I., Briganti A., Carrio I., Chiti A., Clarke N., Eiber M., De Bono J., et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018;19:e696–e708. doi: 10.1016/S1470-2045(18)30604-1.
    1. Annunziata S., Pizzuto D.A., Treglia G. Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses. Cancers. 2020;12:2153. doi: 10.3390/cancers12082153.
    1. Okarvi S.M. Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: An overview. Clin. Transl. Imaging. 2019;7:189–208. doi: 10.1007/s40336-019-00326-3.
    1. Ceci F., Fanti S. PSMA-PET/CT imaging in prostate cancer: Why and when. Clin. Transl. Imaging. 2019;7:377–379. doi: 10.1007/s40336-019-00348-x.
    1. Ceci F., Castellucci P., Fanti S. Current application and future perspectives of PSMA PET imaging in prostate cancer. Q. J. Nucl. Med. Mol. Imaging. 2019;63:7–18. doi: 10.23736/S1824-4785.18.03059-5.
    1. Von Eyben F.E., Baumann G.S., Baum R.P. PSMA diagnostics and treatments of prostate cancer become mature. Clin. Transl. Imaging. 2018;6:145–148. doi: 10.1007/s40336-018-0270-2.
    1. Treglia G., Mestre R.P., Ferrari M., Bosetti D.G., Pascale M., Oikonomou E., De Dosso S., Jermini F., O Prior J., Roggero E., et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: A meta-analysis. Am. J. Nucl. Med. Mol. Imaging. 2019;9:127–139.
    1. Mestre R.P., Treglia G., Ferrari M., Pascale M., Mazzara C., Azinwi N.C., Llado’ A., Stathis A., Giovanella L., Roggero E. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis. Eur. J. Clin. Investig. 2018;49:e13063. doi: 10.1111/eci.13063.
    1. Sengupta S., Krishnan M.A., Chattopadhyay S., Chelvam V. Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. Cancer Rep. 2019;2:e1169. doi: 10.1002/cnr2.1169.
    1. Eiber M., Fendler W.P., Rowe S.P., Calais J., Hofman M.S., Maurer T., Schwarzenboeck S.M., Kratowchil C., Herrmann K., Giesel F.L. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J. Nucl. Med. 2017;58:67S–76S. doi: 10.2967/jnumed.116.186767.
    1. Gourni E., Henriksen G. Metal-Based PSMA Radioligands. Molecules. 2017;22:523. doi: 10.3390/molecules22040523.
    1. Czarniecki M., Mena E., Lindenberg L., Cacko M., Harmon S., Radtke J.P., Giesel F., Turkbey B., Choyke P.L. Keeping up with the prostate-specific membrane antigens (PSMAs): An introduction to a new class of positron emission tomography (PET) imaging agents. Transl. Androl. Urol. 2018;7:831–843. doi: 10.21037/tau.2018.08.03.
    1. Zippel C., Ronski S.C., Bohnet-Joschko S., Giesel F.L., Kopka K. Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on . Pharmaceuticals. 2020;13:12. doi: 10.3390/ph13010012.
    1. Pastorino S., Riondato M., Uccelli L., Giovacchini G., Giovannini E., Duce V., Ciarmiello A. Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Curr. Radiopharm. 2020;13:63–79. doi: 10.2174/1874471012666190729151540.
    1. Wester H.-J., Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin. Nucl. Med. 2019;49:302–312. doi: 10.1053/j.semnuclmed.2019.02.008.
    1. Foley R., Redman S., Graham R., Loughborough W., Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography–computed tomography: Normal patterns, pearls, and pitfalls. Clin. Radiol. 2020;75:903–913. doi: 10.1016/j.crad.2020.06.031.
    1. Cardinale J., Schäfer M., Benešová M., Bauder-Wüst U., Leotta K., Eder M., Neels O.C., Haberkorn U., Giesel F.L., Kopka K. Preclinical Evaluation of 18 F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J. Nucl. Med. 2016;58:425–431. doi: 10.2967/jnumed.116.181768.
    1. Treglia G., Annunziata S., Pizzuto D.A., Giovanella L., Prior J.O., Ceriani L. Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers. 2019;11:710. doi: 10.3390/cancers11050710.
    1. McInnes M.D.F., Moher D., Thombs B.D., McGrath T.A., Bossuyt P.M., the PRISMA-DTA Group Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319:388–396. doi: 10.1001/jama.2017.19163.
    1. Sadeghi R., Treglia G. Systematic reviews and meta-analyses of diagnostic studies: A practical guideline. Clin. Transl. Imaging. 2017;5:83–87. doi: 10.1007/s40336-016-0219-2.
    1. [(accessed on 31 December 2020)]; Available online: .
    1. Anttinen M., Ettala O., Malaspina S., Jambor I., Sandell M., Kajander S., Rinta-Kiikka I., Schildt J., Saukko E., Rautio P., et al. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE) Eur. Urol. Oncol. 2020 doi: 10.1016/j.euo.2020.06.012.
    1. Giesel F.L., Hadaschik B., Cardinale J., Radtke J., Vinsensia M., Lehnert W., Kesch C., Tolstov Y., Singer S., Grabe N., et al. F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:678–688. doi: 10.1007/s00259-016-3573-4.
    1. Giesel F.L., Will L., Lawal I., Lengana T., Kratochwil C., Vorster M., Neels O., Reyneke F., Haberkorn U., Kopka K., et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J. Nucl. Med. 2018;59:1076–1080. doi: 10.2967/jnumed.117.204669.
    1. Hong J.-J., Liu B.-L., Wang Z.-Q., Tang K., Ji X.-W., Yin W.-W., Lin J., Zheng X.-W. The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer. EJNMMI Res. 2020;10:1–8. doi: 10.1186/s13550-020-00730-1.
    1. Kesch C., Vinsensia M., Radtke J.P., Schlemmer H.P., Heller M., Ellert E., Holland-Letz T., Duensing S., Grabe N., Afshar-Oromieh A., et al. Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. J. Nucl. Med. 2017;58:1805–1810. doi: 10.2967/jnumed.116.189233.
    1. Kuten J., Fahoum I., Savin Z., Shamni O., Gitstein G., Hershkovitz D., Mabjeesh N.J., Yossepowitch O., Mishani E., Even-Sapir E. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J. Nucl. Med. 2019;61:527–532. doi: 10.2967/jnumed.119.234187.
    1. Privé B.M., Israël B., Schilham M.G.M., Muselaers C.H.J., Zámecnik P., Mulders P.F.A., Witjes J.A., Sedelaar M., Mehra N., Verzijlbergen F., et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2020:1–8. doi: 10.1038/s41391-020-00292-2.
    1. Sprute K., Kramer V., Koerber S.A., Meneses M., Fernandez R., Soza-Ried C., Eiber M., Weber W.A., Rauscher I., Rahbar K., et al. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J. Nucl. Med. 2021;62:208–213. doi: 10.2967/jnumed.120.246363.
    1. Treglia G., Sadeghi R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: The state of the art. Clin. Transl. Imaging. 2013;1:73–75. doi: 10.1007/s40336-013-0013-3.
    1. Rahbar K., Afshar-Oromieh A., Seifert R., Wagner S., Schäfers M., Bögemann M., Weckesser M. Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel? World J. Nucl. Med. 2020;19:220–223. doi: 10.4103/wjnm.WJNM_6_19.
    1. Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl. Radiat. Isot. 2013;76:55–62. doi: 10.1016/j.apradiso.2012.06.034.
    1. Bunka M., Müller C., Vermeulen C., Haller S., Türler A., Schibli R., van der Meulen N.P. Imaging quality of 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. Appl. Radiat. Isot. 2016;110:129–133. doi: 10.1016/j.apradiso.2016.01.006.
    1. Mottet N., Bergh R.C.V.D., Briers E., Broeck T.V.D., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2021;79:243–262. doi: 10.1016/j.eururo.2020.09.042.
    1. Hofman M.S., Lawrentschuk N., Francis R.J., Tang C., Vela I., Thomas P., Rutherford N., Martin J.M., Frydenberg M., Shakher R., et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet. 2020;395:1208–1216. doi: 10.1016/S0140-6736(20)30314-7.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다